Latest Materials News

TasFoods has announced a delay in lodging its 2025 annual report due to an ongoing, material sale transaction, keeping its shares suspended until further notice.

Cynata Therapeutics reported a reduced half-year loss alongside progress in pivotal clinical trials, extending its cash runway into mid-2026. Investors await critical data from Phase 3 and Phase 2 studies expected in the coming months.

Duxton Farms Limited reported a significant half-year loss driven by acquisition and integration costs following a major portfolio expansion. The company is navigating a strategic shift towards diversified agriculture with plans to stabilise earnings over the coming years.

Lowell Resources Fund reported a remarkable 63% increase in net asset value for the half-year ending December 2025, driven by a strategic overweight in gold equities and buoyed by soaring commodity prices.

Australian Dairy Nutritionals Group has cut its net loss by 40% in the half-year to December 2025, driven by a remarkable 431% revenue jump in its nutritional powders segment amid expanding Chinese distribution.

Alpha HPA Limited reported a $22.5 million loss for the half-year ending December 2025, driven by ongoing investment in its HPA First Project. Despite the loss, strong demand from semiconductor and battery sectors and a recent $225 million capital raise position the company for significant growth.

LDR Capital Property Fund has locked in a lease renewal with the Commonwealth Government at Garema Court, extending tenancy to 2030 and significantly reducing near-term leasing risk.

MCS Services Limited has finalized a revised agreement to sell the core assets of its subsidiary Highways Traffic Pty Ltd to Altus Traffic for $1.16 million, pending shareholder approval. This marks a strategic step in MCS’s ongoing business realignment following the sale of its larger security division.

NOVONIX Limited posted a $92.7 million net loss for 2025 while progressing its synthetic graphite anode materials business and preparing to divest its Battery Technology Solutions segment.

Percheron Therapeutics reports a 64% reduction in half-year losses to $3.1 million, driven by progress in its licensed immuno-oncology drug HMBD-002 and a strategic pivot away from discontinued assets.

Vectus Biosystems reports a narrowed half-year loss as it advances clinical drug VB0004 and nears a key asset sale to XORTX Therapeutics.

Pengana Private Equity Trust reported a significant decline in half-year profit for the period ending 31 December 2025, yet increased its interim distribution to unitholders. The Trust’s net asset value per unit showed a modest rise despite challenging market conditions.